ARTL — ARTELO BIOSCIENCES, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1621221 ·
Last close
$1.68
Market Cap
$1.57M
52W High
$179.19
52W Low
$1.62
ADV30
36,771
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -2,505,000 | -2,427,000 | 6,459,000 | 4,198,000 | 1,462,000 |
| Mar 2026 | 0 | — | -2,689,000 | -2,958,000 | 12,518,000 | 10,273,000 | 5,846,000 |
| Dec 2025 | 0 | — | -2,786,000 | -4,166,000 | 2,801,000 | 600,000 | 4,073,000 |
| Sep 2025 | 0 | — | -3,089,000 | -3,120,000 | 4,267,000 | 1,720,000 | 4,900,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,633,000
Investing CF
$-62,000
Financing CF
$14,847,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-33.66
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-68,400,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-12,336,000
Pretax Income TTM
$-12,671,000
Interest Exp TTM
$335,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -11,404,000 | -12,879,000 | 2,801,000 | 4,073,000 | -1,272,000 | -8,520,000 |
| Dec 2024 | 0 | -10,108,000 | -9,826,000 | 4,698,000 | 1,841,000 | 2,857,000 | -8,350,000 |
| Dec 2023 | 0 | -9,930,000 | -9,289,000 | 13,043,000 | 1,291,000 | 11,752,000 | -8,207,000 |
| Dec 2022 | 0 | -10,287,000 | -10,083,000 | 20,424,000 | 1,021,000 | 19,403,000 | -8,008,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-12,671,000
OpCashFlow TTM
—
Assets (Latest)
$6,459,000
Forward EPS
$-0.88
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EMMA | Emmaus Life Sciences, Inc. | $1.61M | $0.02 | — |
| LIFD | LFTD PARTNERS INC. | $1.63M | $0.11 | — |
| RNAZ | Transcode Therapeutics, Inc. | $1.49M | $1.41 | — |
| HCWB | HCW Biologics Inc. | $1.43M | $0.78 | — |
| CPMD | CANNAPHARMARX, INC. | $1.42M | $0.00 | — |
News headlines (Yahoo Finance, 1h cache)
Artelo Biosciences Provides Business Update and Reports 2026 Third Quarter Financial Results
2026-11-12 13:00 · Yahoo
Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain
2026-10-29 13:00 · Yahoo
Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
2026-10-26 11:55 · Yahoo
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
2026-10-07 12:48 · Yahoo
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
2026-09-23 11:33 · Yahoo
Artelo Biosciences Announces Reverse Stock Split
2026-08-27 12:00 · Yahoo
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
2026-08-17 12:52 · Yahoo
Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
2026-08-13 12:00 · Yahoo
New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition
2026-07-22 12:39 · Yahoo
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
2026-07-16 12:48 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.